MX2021012386A - Proteínas de union triespecíficas, métodos y usos de las mismas. - Google Patents

Proteínas de union triespecíficas, métodos y usos de las mismas.

Info

Publication number
MX2021012386A
MX2021012386A MX2021012386A MX2021012386A MX2021012386A MX 2021012386 A MX2021012386 A MX 2021012386A MX 2021012386 A MX2021012386 A MX 2021012386A MX 2021012386 A MX2021012386 A MX 2021012386A MX 2021012386 A MX2021012386 A MX 2021012386A
Authority
MX
Mexico
Prior art keywords
binding
binding proteins
polypeptide
binds
proteins
Prior art date
Application number
MX2021012386A
Other languages
English (en)
Spanish (es)
Inventor
Ronnie Wei
Huawei Qiu
Béatrice Cameron
Tarik Dabdoubi
Cendrine Lemoine
Joerg Birkenfeld
Zhi- Yong YANG
Gary J Nabel
Ling Xu
Lan Wu
Edward Seung
Catherine Prades
Joerg Regula
Zhen Xing
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021012386A publication Critical patent/MX2021012386A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021012386A 2019-04-09 2020-04-08 Proteínas de union triespecíficas, métodos y usos de las mismas. MX2021012386A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831572P 2019-04-09 2019-04-09
EP19306261 2019-10-02
PCT/US2020/027320 WO2020210392A1 (en) 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof

Publications (1)

Publication Number Publication Date
MX2021012386A true MX2021012386A (es) 2022-01-18

Family

ID=72751423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012386A MX2021012386A (es) 2019-04-09 2020-04-08 Proteínas de union triespecíficas, métodos y usos de las mismas.

Country Status (13)

Country Link
EP (1) EP3953388A1 (zh)
JP (1) JP2022527994A (zh)
KR (1) KR20210149141A (zh)
CN (1) CN113950484A (zh)
AU (1) AU2020272839A1 (zh)
BR (1) BR112021019915A2 (zh)
CA (1) CA3136821A1 (zh)
CO (1) CO2021014918A2 (zh)
IL (1) IL286929A (zh)
MX (1) MX2021012386A (zh)
SG (1) SG11202111012QA (zh)
TW (1) TW202104261A (zh)
WO (1) WO2020210392A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024077118A2 (en) * 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI803876B (zh) * 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
ES2808914T3 (es) * 2014-09-04 2021-03-02 Stemcell Tech Inc Complejos de anticuerpo solubles para la activación y expansión de linfocitos T o células NK
BR112017014805A2 (pt) * 2015-01-23 2018-01-09 Sanofi anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam especificamente a cd3 e/ou cd123
JP2018524312A (ja) * 2015-06-17 2018-08-30 ジェネンテック， インコーポレイテッド 抗ｈｅｒ２抗体及び使用方法
RS62437B1 (sr) 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
WO2018120842A1 (zh) * 2016-12-30 2018-07-05 上海欣百诺生物科技有限公司 一种双功能分子及其应用
EA201892312A1 (ru) 2017-03-17 2019-04-30 Санофи Триспецифические и/или тривалентные связывающие белки
CN117964758A (zh) * 2017-10-10 2024-05-03 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
BR112021006558A2 (pt) * 2018-10-09 2021-07-13 Sanofi proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral

Also Published As

Publication number Publication date
EP3953388A1 (en) 2022-02-16
CN113950484A (zh) 2022-01-18
AU2020272839A1 (en) 2021-12-02
WO2020210392A1 (en) 2020-10-15
JP2022527994A (ja) 2022-06-07
BR112021019915A2 (pt) 2021-12-07
TW202104261A (zh) 2021-02-01
CA3136821A1 (en) 2020-10-15
KR20210149141A (ko) 2021-12-08
IL286929A (en) 2021-10-31
SG11202111012QA (en) 2021-11-29
CO2021014918A2 (es) 2021-11-19

Similar Documents

Publication Publication Date Title
WO2017180913A3 (en) Trispecific and/or trivalent binding proteins
MX2022014631A (es) Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih.
HRP20210041T1 (hr) Kovalentno vezana diatijela koja imaju imunoreaktivnost s pd-1 i lag-3, i postupci njihove uporabe
MX2019008496A (es) Aglutinantes de albumina serica mejorados.
MX2023007520A (es) Aglutinantes de albumina de suero mejorados.
PH12019500609A1 (en) Cd123 binding proteins and related compositions and methods
MX2019008536A (es) Aglutinantes de albumina serica mejorados.
MY164906A (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
AU2018256592A1 (en) Binding proteins comprising at least two repeat domains against HER2
WO2019074973A3 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
JP2017526632A5 (zh)
MX2021007947A (es) Terapeuticos de anticuerpo que se unen a ctla4.
MX2019003350A (es) .anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina.
PH12020500137A1 (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
MX351502B (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
EA202090718A1 (ru) Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
PH12014501818A1 (en) Pseudomonas aeruginosa pcrv binding single variable domain antibodies
EP4257193A3 (en) Trispecific and/or trivalent binding proteins
MX2021012386A (es) Proteínas de union triespecíficas, métodos y usos de las mismas.
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
MX2021012384A (es) Proteínas de union triespecíficas y/o trivalentes que utilizan el formato de dominio variable cruzado doble (codv) para el tratamiento de la infección por vih.
MX2022007919A (es) Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).
ATE492564T1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum